These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

708 related items for PubMed ID: 16265686

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Reduction of soluble adhesion molecules (sICAM-1, sVCAM-1, and sE-selectin) and vascular endothelial growth factor levels in serum of rheumatoid arthritis patients following multiple intravenous infusions of infliximab.
    Klimiuk PA, Sierakowski S, Domysławska I, Fiedorczyk M, Chwiećko J.
    Arch Immunol Ther Exp (Warsz); 2004; 52(1):36-42. PubMed ID: 15053231
    [Abstract] [Full Text] [Related]

  • 3. Effect of etanercept on serum levels of soluble cell adhesion molecules (sICAM-1, sVCAM-1, and sE-selectin) and vascular endothelial growth factor in patients with rheumatoid arthritis.
    Klimiuk PA, Sierakowski S, Domyslawska I, Chwiecko J.
    Scand J Rheumatol; 2009; 38(6):439-44. PubMed ID: 19922018
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Serum tumor necrosis factor alpha (TNF-alpha) concentration correlates with soluble adhesion molecules and vascular endothelial growth factor (VEGF) in rheumatoid arthritis].
    Klimiuk PA, Sierakowski S, Fiedorczyk M, Chwiećko J.
    Przegl Lek; 2004; 61(2):86-9. PubMed ID: 15230147
    [Abstract] [Full Text] [Related]

  • 8. Influence of anti-TNF-alpha infliximab therapy on adhesion molecules associated with atherogenesis in patients with rheumatoid arthritis.
    Gonzalez-Gay MA, Garcia-Unzueta MT, De Matias JM, Gonzalez-Juanatey C, Garcia-Porrua C, Sanchez-Andrade A, Martin J, Llorca J.
    Clin Exp Rheumatol; 2006; 24(4):373-9. PubMed ID: 16956426
    [Abstract] [Full Text] [Related]

  • 9. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy.
    Kavanaugh A, St Clair EW, McCune WJ, Braakman T, Lipsky P.
    J Rheumatol; 2000 Apr; 27(4):841-50. PubMed ID: 10782805
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial.
    Smolen JS, Van Der Heijde DM, St Clair EW, Emery P, Bathon JM, Keystone E, Maini RN, Kalden JR, Schiff M, Baker D, Han C, Han J, Bala M, Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset (ASPIRE) Study Group.
    Arthritis Rheum; 2006 Mar; 54(3):702-10. PubMed ID: 16508926
    [Abstract] [Full Text] [Related]

  • 12. Infliximab treatment reduces the serum levels of interleukin-23 in patients with rheumatoid arthritis.
    Kageyama Y, Kobayashi H, Kato N.
    Mod Rheumatol; 2009 Mar; 19(6):657-62. PubMed ID: 19685204
    [Abstract] [Full Text] [Related]

  • 13. Preliminary evaluation in rheumatoid arthritis activity in patients treated with TNF-alpha blocker plus methotrexate versus methotrexate or leflunomide alone.
    Wisłowska M, Jakubicz D.
    Rheumatol Int; 2007 May; 27(7):641-7. PubMed ID: 17235556
    [Abstract] [Full Text] [Related]

  • 14. Soluble cell adhesion molecules (sICAM-1, sVCAM-1, and sE-selectin) in patients with early rheumatoid arthritis.
    Klimiuk PA, Fiedorczyk M, Sierakowski S, Chwiecko J.
    Scand J Rheumatol; 2007 May; 36(5):345-50. PubMed ID: 17963163
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Anti-tumor necrosis factor-alpha response in rheumatoid arthritis is associated with an increase in serum soluble CD30.
    Gerli R, Lunardi C, Bocci EB, Bobbio-Pallavicini F, Schillaci G, Caporali R, Bistoni O, Pirro M, Pitzalis C, Montecucco C.
    J Rheumatol; 2008 Jan; 35(1):14-9. PubMed ID: 18061981
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.